Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Eli Lilly blamed the shortfall on lower-than-anticipated demand for its weight-loss drugs. Indeed, the drug maker ...
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback